

## Curriculum vitae

**Elisa Garlassi, MD, PhD, Infectious Disease Specialist**

Born in Reggio Emilia (R.E), Italy, on July 7, 1981,

Resident in Reggio Emilia, via Bonvicini 24/1, Reggio Emilia (CAP 42122) C.F. GRLLSE81L47H223Z,

### AT HOME TRAINING

July 2000	<b>School-leaving examination</b> at "Aldo Moro" Scientific Liceo in Reggio Emilia, Italy, passed in July 2000 with 98/100.
October 2006	<b>Graduation</b> in Medicine and Surgery at the University of Modena and Reggio Emilia, Italy.  She discussed a degree thesis entitled: " <i>Homocysteinemia to evaluate cardiovascular risk in HIV-infected patients:</i> " with full marks and laude.
November 2006 - February 2007	Trained in Internal Medicine at Modena and Reggio Emilia University, Italy, where clinical rotations (Emergency, Internal Medicine and Surgery) required for licensure were performed. <b>State licensure examination</b> passed in February 2007.
July 2007-2011	<b>Attended Infectious Diseases Specialization Course</b> at the University of Modena and Reggio Emilia, Italy. She discussed a thesis entitled: " <i>Prognostic risk factors of Hodgkin disease in HIV-infected individuals</i> " with full marks and laude.
Oct 2007	Attended the course "Malaria: microscopy diagnosis", Sacro Cuore-Don Calabria Hospital, Negrar (VR) from Oct 8 <sup>th</sup> to Oct 10 <sup>th</sup>
	<b>Attended International Doctorate School (PhD) in Clinical and Experimental Medicine (CEM)</b>

March 2012- 2015

### WORKING EXPERIENCE

July 2011- June 2013	Counselling and care of Injection Drug Users on the road (Drug Addiction Service).
Sept-2011- Sept 2013	Research fellowship with the title "Oncohematological diseases in patients with HIV infection".
Jan2012-ongoing	Clinical and Experimental Medicine Doctorate School (PhD) at the University of Modena and Reggio Emilia, Italy.
March 2012- Sept 2013	Infectious Disease physician at Sant'Anna Public Prison, Modena, Italy
Sept 2013- ongoing	Infectious Disease physician at Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy
Sept 2013-ongoing	Infectious Disease physician at Public Prison, Reggio Emilia, Italy

## ABROAD TRAINING AND RESEARCH PERIODS

March 2005-	<u>Nazareth Hospital-Nairobi (Kenya)</u>
June 2005	She attended, during 5 <sup>th</sup> university year, three months in Nairobi attending at clinical practice in Gynecology, Pediatric and Antenatal HIV clinic.
November 2008 – ongoing	<u>National Cancer Institute – Aviano (Italy)</u>  She attended, during Infectious Disease School of Specialization, four months at Medical Oncology Department in National Cancer Institute.  Collaboration is ongoing in various fields, especially on haematological disease in HIV (Burkitt, Hodgkin) and solid tumors in HIV (HCC, anal cancer, colorectal cancer).  <u>Chelsea and Westminster Hospital-London (UK)</u>  She attended, as clinical observer, Medical Oncology Department at Chelsea and Westminster Hospital (London, UK), one of the largest centres for the management of AIDS related malignancies in Europe. Supervisor prof. Mark Bower, medical oncologist at Chelsea & Westminster Hospital and Professor at Imperial College
Oct 2011- Dec 2011	

## CLINICAL AND RESEARCH ACTIVITIES

Her major field of interest concerns Oncohematology in HIV, Cardiovascular disease in HIV, Aging and comorbidities in HIV.

She is involved as investigator in some national and international clinical trials (hematology in HIV, oncology in HIV, new antibiotic therapy):

**Clinical Trial 1182.71: POTENT:** Prospective Evaluation of Tipranavir vs Darunavir in treatment experienced patients

**Clinical Trial 101.1.C.004:** A multinational-multicenter, double-blind, randomized, parallel group study to compare the safety and efficacy of 200 mg par 101 taken q12h with 125 mg vancomycin taken q6h for ten days in subjects with clostridium difficile-associated diarrhea.

**Clinical Trial AC-061A201** “A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-179811 in subjects with Clostridium difficile infection (CDI)”.

**Clinical Trial 2010-023602-12:** Studio di fattibilità che valuta l'efficacia e la tolleranza del Sorafenib (NEXAVAR) associato alla terapia antiretrovirale altamente efficace (HAART) nei pazienti con infezione da HIV ed epatocarcinoma avanzato.

**Clinical Trial:** “A global multi-center retrospective cohort study to investigate hepatocellular carcinoma in HIV-infected patients”.

**Studio nazionale trasversale PREVIC 2013:** Infezione da HIV e Profilassi Pre-Esposizione in Italia

**Clinical Trial HIRMA:** “Studio multidisciplinare finalizzato all'identificazione e caratterizzazione di marker innovativi in grado di definire il ruolo di virus epatotropi nello sviluppo del carcinoma epatocellulare”

# SCIENTIFIC PUBLICATIONS IN INTERNATIONAL JOURNALS

2008	<p><b>Lipodystrophy and quality of life of HIV-infected persons</b></p> <p>Guaraldi G, Murri R, Orlando G, Squillace N, Stentarelli C, Zona S, <b>Garlassi E</b>, Martínez E.</p> <p>AIDS Rev. 2008 Jul-Sep;10(3):152-61. Review.PMID: 18820717</p>
2009	<p><b>Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease</b></p> <p>Guaraldi G, Ventura P, <b>Garlassi E</b>, Orlando G, Squillace N, Nardini G, Stentarelli C, Zona S, Marchini S, Moriondo V, Tebas P.</p> <p>HIV Med. 2009 Jan;10(1):28-34.PMID: 19125962</p>
2010	<p><b>Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection</b></p> <p>Berretta M, Lleshi A, Cappellani A, Bearz A, Spina M, Talamini R, Cacopardo B, Nunnari G, Montesarchio V, Izzi I, Lanzafame M, Nasti G, Basile F, Berretta S, Fisichella R, Schiantarelli C C, <b>Garlassi E</b>, Ridolfo A, Guella L, Tirelli U.</p> <p>Curr HIV Res. 2010 Apr 1;8(3):218-22.PMID: 20158458</p>
2010	<p><b>Unexpected identification of bilateral masses in an asymptomatic heavy smoker</b></p> <p><b>Garlassi E</b>, Rossi G, Bedini A, Richeldi L.</p> <p>Thorax. 2010 Jul 29 PMID: 20671304</p>
2011	<p><b>Hepatocellular carcinoma in HIV infected patients: check early, treat hard</b></p> <p>Berretta M, <b>Garlassi E</b>, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, De Paoli P, Lleshi A, Izzi I, Torresin A, Di Gangi P, Pietrangelo A, Ferrari M, Bearz A, Berretta S, Nasti G, Di Benedetto F, Balestreri L, Tirelli U, Ventura P</p> <p>Oncologist. 2011 Aug 25 PMID: 21868692</p> <p><b>Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study</b></p> <p>Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, <b>Garlassi E</b>, Menozzi M, Bagni P, Adorni F.</p> <p>Clin Drug Investig. 2011 Nov 1;31(11):759-67 PMID: 21919542</p> <p><b>Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General</b></p>

	<p><b>Population</b></p> <p>G. Guaraldi, G.Orlando,S. Zona, M. Menozzi, F. Carli, <b>E. Garlassi</b>, A. Berti, E.Rossi, A. Roverato, and F. Palella</p> <p>Clin Infect Dis. 2011 Oct 13. PMID: 21998278</p>
2012	<p><b>Non-melanoma skin cancers among HIV-infected persons in the HAART-era</b></p> <p><b>Garlassi E.</b>, Harding V., Weir J., Francis N., Nelson M., Tom Newsom-Davis T. &amp; Bower M..</p> <p>J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e63-5.</p>
2013	<p><b>Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.</b></p> <p>Berretta M, Di Benedetto F, Dal Maso L, Cacopardo B, Nasti G, Facchini G, Bearz A, Spina M, <b>Garlassi E</b>, De Re V, Fiorica F, Lleshi A, Tirelli U</p> <p>Anticancer Drugs. 2013 Feb;24(2):212-8.</p>
2013	<p><b>Combine use of waist and hip circumference to identify abdominally obese HIV-infected patients at increased health risk.</b></p> <p>O'Neill T, Guaraldi G, Orlando G, Carli F, <b>Garlassi E</b>, Zona S, Després JP, Ross R.</p> <p>PLoS One. 2013 May 20;8(5):e62538.</p>
2013	<p><b>CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients.</b></p> <p>Guaraldi G, Luzi K, Bellistri GM, Zona S, Domingues da Silva AR, Bai F, <b>Garlassi E</b>, Marchetti G, Capeau J, Monforte Ad.</p> <p>J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):360-6.</p>
2013	<p><b>Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: Monarch randomized controlled trial.</b></p> <p>Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, Nardini G, Orlando G, <b>Garlassi E</b>, Termini R, Garau M.</p> <p>Int J STD AIDS. 2013 Aug 28.</p>
2014	<p><b>Life Expectancy in the Immune Recovery Era: The Evolving Scenario of the HIV Epidemic in Northern Italy.</b></p> <p>Guaraldi G, Cossarizza A, Franceschi C, Roverato A, Vaccher E, Tambussi G, <b>Garlassi E</b>, Menozzi M, Mussini C,</p>

	<p>D'arminio Monforte A.</p> <p>J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):175-81</p>
2014	<p><b>Metabolic Alterations in HIV-Infected Pregnant Women: Moving to Metabolic Tailoring of Antiretroviral Drugs.</b></p> <p>Guaraldi G, Stentarelli C, Domingues Da Silva A, Luzi K, Neri I, Cellini M, Petrella E, <b>Garlassi E</b>, Menozzi M, Facchinetti F, Mussini C.</p> <p>AIDS Rev. 2014 Jan-Mar;16(1):14-22</p>
2014	<p><b>Contrast-enhanced ultrasound (CEUS) appearance of hepatic Myelolipoma</b></p> <p>Guido Menozzi • Valeria Maccabruni • Giulia Marini • Elisabetta Froio • <b>Elisa Garlassi</b></p> <p>J Ultrasound DOI 10.1007/s40477-014-0137-y</p>
2014	<p>Evaluation with contrast ultrasound of the prevalence of splenic infarction in left-sided infective endocarditis.</p> <p><a href="#">Menozzi G</a>; <a href="#">Maccabruni V</a>; <a href="#">Gabbi E</a>; <a href="#">Magnani G</a>; <a href="#">Garlassi E</a>;</p> <p><a href="#">Journal Of Ultrasound</a> 2014 Sep 13; Vol. 18 (3), pp. 223-7.</p>

<b>NATIONAL AND INTERNATIONAL CONGRESS ABSTRACTS</b>	
<b>GASTROINTESTINAL CANCERS IN HIV-POSITIVE PATIENTS</b>	
2009	<p><b>Oral presentation:</b> XXIII Congresso nazionale AIDS e Sindromi correlate, Venice, November 18-20, 2009</p>
<b>THE ODYSSEY OF A LYMPHONODE</b>	
2009	<p><b>Oral presentation:</b> Infectious Diseases Academy (IDA) Messina, October 8-9, 2009</p> <p><u>Winner of first prize for the best report of the meeting series</u></p>

2012	<b>Oral Presentation</b> “5 <sup>th</sup> INFE <i>C</i> tivology TO <i>day</i> ” “L’infettivologia del 3° millennio: AIDS ed altro ” Paestum, May 17-19, 2012
<b>HEPATOCELLULAR CARCINOMA IN HIV INFECTED PATIENTS: CHECK EARLY, TREAT HARD</b>	
2010	<b>Oral presentation</b> 43° Riunione Annuale A.I.S.F. (Rome, February 25-26, 2010)
2010	<b>Poster presentation</b> “EASL Special Conference on Hepatocellular Carcinoma: from Genomics to Treatment”Dubrovnik, Croatia, June 25-26, 2010
2010	<b>Oral Presentation</b> “4 <sup>th</sup> INFE <i>C</i> tivology TO <i>day</i> ” “L’infettivologia del 3° millennio: AIDS ed altro ” Paestum, May 13-15, 2010  <u>Winner of a prize for one of the best presentation of the meeting</u>
2010	<b>Oral Presentation</b> “HIV AND LIVER DISEASE 2010” Third Biennial Meeting, Jackson Hole WY, September 24-26, 2010
2010	<b>Oral Presentation</b> “9° Congresso Nazionale Società Italiana Malattie Infettive e Tropicali (SIMIT 2010)” Roma, November 24-27, 2010
<b>GENDER AND GONADAL FUNCTION DIFFERENCES IN THE PREVALENCE OF BONE MASS REDUCTION</b>	
2009	<b>Poster Presentation</b> “16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)”, Montreal, Canada, February 8-11, 2009 Poster board #754
<b>POLYPHARMACOLOGY FOR POLYPATHOLOGY IN HIV INFECTED PATIENTS</b>	
2010	<b>Poster Presentation</b> “12 <sup>th</sup> International Workshop on Adverse Drug reactions & Co-morbidities in HIV, London, UK, November 4-6, 2010. Poster board # P04

2010	<b>Poster Presentation</b> "9° Congresso Nazionale Società Italiana Malattie Infettive e Tropicali (SIMIT 2010)" Roma, November 24-27, 2010. Poster board # 112
<b>CD4 NADIR AND ANTIRETROVIRAL EXPOSURE PREDICT PREMATURE POLYPATHOLOGY ONSET</b>	
2010	<b>Oral Presentation</b> "9° Congresso Nazionale Società Italiana Malattie Infettive e Tropicali (SIMIT 2010)" Roma, November 24-27, 2010.
2010	<b>Poster Presentation</b> "12 <sup>th</sup> International Workshop on Adverse Drug reactions & Co-morbidities in HIV, London, UK, November 4-6, 2010. Poster board # 011
<b>VISCERAL FAT BUT NOT GENERAL ADIPOSITY IS A PREDICTOR OF CARDIOVASCULAR DISEASE IN HIV-INFECTED MALE</b>	
2010	Poster Presentation "17th Conference on Retroviruses and Opportunistic Infections (CROI 2010), San Francisco, CA, February 16-19, 2010 Poster board # 703
<b>VITAMIN D3 SUPPLEMENTATION DECREASES THE RISK OF DIABETES MELLITUS AMONG PATIENTS WITH HIV INFECTION</b>	
2011	<b>Poster Presentation</b> "18th Conference on Retroviruses and Opportunistic Infections" (CROI 2011), Boston, MA, February 27-March 2, 2011 Poster board # 827
<b>PYRAZINAMIDE AND LEVOFLOXACIN CHEMOPROPHYLAXIS FOR LATENT MULTIDRUG-RESISTANT TUBERCULOSIS: TOLERANCE AND KINETICS OF THE QUANTIFERON -TB GOLD IN-TUBE TEST</b>	
2011	<b>Poster Presentation</b> "51st Interscience Conference on Antimicrobial Agents and Chemotherapy" (ICAAC 2011), Chicago, 17-20 Sept, 2011
<b>NON-MELANOMA SKIN CANCERS AMONG HIV-INFECTED PERSONS IN THE HAART-ERA</b>	
2012	<b>Poster presentation</b> "18th Annual Conference of the British HIV Association (BHIVA)" Birmingham, UK 18-20 April 2012  HIV Medicine 2012, 13 (suppl 1) 34
<b>COMBINED USE OF WAIST AND THIGH CIRCUMFERENCE TO IDENTIFY HIGH-RISK, ABDOMINALLY OBESE HIV+ PATIENTS</b>	

2012	O'Neil T, Ross R, Zona S, Orlando G, Carli F, <b>Garlassi E</b> , Stentarelli C, Mussini C, Guaraldi G.. J Int AIDS Soc. 2012 Nov 11;15(6): 18302
<b>TENOFOVIR ACCELERATES BONE MASS LOSS OF THE LUMBAR SPINE IN THE FIRST YEARS OF MENOPAUSE IN HIV-INFECTED WOMEN.</b>	
2012	Garlassi E, Zona S, Vescini F, Domingues da Silva A, Berardi C, Orlando G, Carli F, Menozzi M, Santoro A, Mussini C, Guaraldi G. J Int AIDS Soc. 2012 Nov 11;15(6): 18317

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

Dichiaro che le pubblicazioni sono conformi all'originale

**Personal Address:**

Dr. Elisa Garlassi, MD

Via Bonvicini 24/1

42122 Reggio Emilia, Italy

Cel: +39 340 5198433

e-mail: [elisa.garlassi@gmail.com](mailto:elisa.garlassi@gmail.com)

Reggio Emilia, 3 Luglio 2017

Elisa Garlassi

R  
e  
g  
g  
i  
o

E  
m  
i  
l  
i  
a  
,

2  
9  
/  
0  
6  
/  
2  
0